Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotechnology Company announced the discontinuation of dosing in the first cohort of its candidate ALG-020572, intended for the treatment of chronic hepatitis B. The dosing was stopped after a patient experienced a serious adverse event (SAE) and a...
On March 14 2022, The Nektar Therapeutics (NASDAQ: NKTR) announced that a review by an independent Data Monitoring Committee (DMC) evaluating the safety and efficacy of bempegaldesleukin in combination with Opdivo (nivolumab), revealed that the study has failed to meet the primary endpoints of progression-free...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a clinical-stage biotechnology Company is focussed on creating novel therapeutics for the treatment of neurodegenerative diseases such as ALS and Alzheimer’s. The Company is awaiting the decision on its NDA for AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO; also...
